MARKET

TXMD

TXMD

TherapeuticsMD
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.370
+0.030
+2.24%
After Hours: 1.370 0 0.00% 14:57 11/27 EST
OPEN
1.350
PREV CLOSE
1.340
HIGH
1.410
LOW
1.340
VOLUME
2.06M
TURNOVER
--
52 WEEK HIGH
2.930
52 WEEK LOW
0.8530
MARKET CAP
405.86M
P/E (TTM)
-1.9323
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
TherapeuticsMD Announces Participation in the Stifel 2020 Virtual Healthcare Conference
TXMD to present at Stifel 2020 Virtual Healthcare Conference on Tuesday, Nov. 17 at 9:20 a.m. ET; see details for live webcast
Business Wire · 11/13 12:00
Analyst Estimates: Here's What Brokers Think Of TherapeuticsMD, Inc. (NASDAQ:TXMD) After Its Third-Quarter Report
TherapeuticsMD, Inc. (NASDAQ:TXMD) just released its latest third-quarter results and things are looking bullish...
Simply Wall St. · 11/11 17:29
TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD. The offering is expected to close on or about November 12, 2020, subject to customary closing conditions. In addition, TherapeuticsMD has granted the underwriter a 30-day option to purchase up to approximately 3.5 million additional shares of common stock.
Business Wire · 11/10 13:58
TherapeuticsMD (TXMD) Reports Q3 Loss, Tops Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09 13:15
Therapeutics MD EPS beats by $0.01, beats on revenue
Therapeutics MD (TXMD): Q3 GAAP EPS of -$0.12 beats by $0.01.Revenue of $19.34M (-18.5% Y/Y) beats by $3.9M.Gross margin increased to 83%, compared to 59% for the quarter ended June 30,
Seekingalpha · 11/09 11:57
ROCE Insights For TherapeuticsMD
During Q2, TherapeuticsMD (NASDAQ: TXMD) brought in sales totaling $10.70 million. However, earnings decreased 11.55%, resulting in a loss of $45.04 million. TherapeuticsMD collected $12.25 million in revenue during Q1, but reported earnings showed a $50.92 million loss.Why ROCE Is Significant Changes in earnings and sales indicate shifts in TherapeuticsMD's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, TherapeuticsMD posted an ROCE of 0.48%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on TXMDROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows TherapeuticsMD is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In TherapeuticsMD's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.Q2 Earnings Recap TherapeuticsMD reported Q2 earnings per share at $-0.19/share, which did not meet analyst predictions of $-0.17/share.See more from Benzinga * Click here for options trades from Benzinga * Return On Capital Employed Overview: Apple * Return On Capital Employed Overview: Twilio(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 10/26 14:01
TherapeuticsMD Shares Quiet; Co Granted U.S. Patent No. 10,806,740 Titled 'Natural combination hormone replacement formulations and therapies'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=TherapeuticsMD&OS=TherapeuticsMD&RS=TherapeuticsMD
Benzinga · 10/20 15:06
TherapeuticsMD rallies; to meet Q3 revenue consensus
TherapeuticsMD (TXMD) +6.1% PM, believes that the company is on track to meet or exceed Q3 total net revenue consensus of $15.1M.For the ANNOVERA product, orders to wholesalers, retail pharmacies and online distributors across
Seekingalpha · 09/25 13:16
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TXMD. Analyze the recent business situations of TherapeuticsMD through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TXMD stock price target is 6.90 with a high estimate of 13.00 and a low estimate of 1.200.
EPS
Institutional Holdings
Institutions: 244
Institutional Holdings: 174.37M
% Owned: 58.86%
Shares Outstanding: 296.25M
TypeInstitutionsShares
Increased
31
9.02M
New
37
4.38M
Decreased
48
7.54M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.12%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Tommy Thompson
President/Secretary
John Milligan
Chief Executive Officer/Director
Robert Finizio
Co-Founder
Brian Bernick
Chief Financial Officer
James D'Arecca
Chief Information Officer
Adam Miller
Chief Compliance Officer
John Knighton
Vice President - Finance
Michael Donegan
General Counsel
Marlan Walker
Other
Dawn Halkuff
Other
Mitchell Krassan
Other
Sebastian Mirkin
Other
Bharat Warrier
Independent Director
Paul Bisaro
Independent Director
J. Martin Carroll
Independent Director
Cooper Collins
Independent Director
Karen Ling
Independent Director
Jules Musing
Independent Director
Gail Naughton
Independent Director
Angus Russell
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TXMD
TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of TherapeuticsMD Inc stock information, including NASDAQ:TXMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TXMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TXMD stock methods without spending real money on the virtual paper trading platform.